A mouse model of lethal infection for evaluating prophylactics and therapeutics against monkeypox virus

Journal of Virology

Volumn 84, Issue 8, 2010, Pages 3909-3920

  Stabenow, Jennifer ^a,c   Buller, R Mark ^a   Schriewer, Jill ^a   West, Cheri ^a   Sagartz, John E ^b   Parker, Scott ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Seventh Wave Laboratories   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; GAMMA INTERFERON; INTERFERON; SMALLPOX VACCINE; ST 246; STAT1 PROTEIN; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CYTOSINE; DRUG DERIVATIVE; ISOINDOLE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; ST-246; STAT1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MALE; MONKEYPOX; MONKEYPOX VIRUS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION; VACCINIA VIRUS; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; LIVER; LUNG; MOUSE MUTANT; PATHOGENICITY; SPLEEN; SURVIVAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANIMALIA; MAMMALIA; MONKEYPOX VIRUS; MURINAE; ORTHOPOXVIRUS; VACCINIA VIRUS ANKARA; VARIOLA; VARIOLA VIRUS;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CYTOSINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; ISOINDOLES; LIVER; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONKEYPOX; MONKEYPOX VIRUS; PHOSPHONIC ACIDS; SMALLPOX VACCINE; SPLEEN; STAT1 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINIA VIRUS; VIRAL LOAD;

EID: 77950482298     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02012-09     Document Type: Article

References (63)

1. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15: 749-795.
2. Brandt, T., M. C. Heck, S. Vijaysri, G. M. Jentarra, J. M. Cameron, and B. L. Jacobs. 2005. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology 333: 263-270.
3. Buller, R. M., G. Owens, J. Schriewer, L. Melman, J. R. Beadle, and K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318: 474-481.
4. Chapgier, A., S. Boisson-Dupuis, E. Jouanguy, G. Vogt, J. Feinberg, A. Prochnicka-Chalufour, A. Casrouge, K. Yang, C. Soudais, C. Fieschi, O. F. Santos, J. Bustamante, C. Picard, L. de Beaucoudrey, J. F. Emile, P. D. Arkwright, R. D. Schreiber, C. Rolinck-Werninghaus, A. Rosen-Wolff, K. Magdorf, J. Roesler, and J. L. Casanova. 2006. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet. 2: e131.
5. Chapgier, A., R. F. Wynn, E. Jouanguy, O. Filipe-Santos, S. Zhang, J. Feinberg, K. Hawkins, J. L. Casanova, and P. D. Arkwright. 2006. Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J. Immunol. 176: 5078-5083.
6. Chen, N., G. Li, M. K. Liszewski, J. P. Atkinson, P. B. Jahrling, Z. Feng, J. Schriewer, C. Buck, C. Wang, E. J. Lefkowitz, J. J. Esposito, T. Harms, I. K. Damon, R. L. Roper, C. Upton, and R. M. Buller. 2005. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340: 46-63.
7. Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270: 15974-15978.
8. Dupuis, S., C. Dargemont, C. Fieschi, N. Thomassin, S. Rosenzweig, J. Harris, S. M. Holland, R. D. Schreiber, and J. L. Casanova. 2001. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293: 300-303.
9. Dupuis, S., E. Jouanguy, S. Al Hajjar, C. Fieschi, I. Z. Al Mohsen, S. Al Jumaah, K. Yang, A. Chapgier, C. Eidenschenk, P. Eid, A. Al Ghonaium, H. Tufenkeji, H. Frayha, S. Al Gazlan, H. Al Rayes, R. D. Schreiber, I. Gresser, and J. L. Casanova. 2003. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33: 388-391.
10. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
11. Esteban, D. J., and R. M. Buller. 2005. Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 86: 2645-2659.
12. García-Sastre, A., R. K. Durbin, H. Zheng, P. Palese, R. Gertner, D. E. Levy, and J. E. Durbin. 1998. The role of interferon in influenza virus tissue tropism. J. Virol. 72: 8550-8558.
13. Gavrilescu, L. C., B. A. Butcher, L. Del Rio, G. A. Taylor, and E. Y. Denkers. 2004. STAT1 is essential for antimicrobial effector function but dispensable for gamma interferon production during Toxoplasma gondii infection. Infect. Immun. 72: 1257-1264.
14. Guarner, J., B. J. Johnson, C. D. Paddock, W. J. Shieh, C. S. Goldsmith, M. G. Reynolds, I. K. Damon, R. L. Regnery, and S. R. Zaki. 2004. Monkeypox transmission and pathogenesis in prairie dogs. Emerg. Infect. Dis. 10: 426-431.
15. Hogan, R. J., G. Gao, T. Rowe, P. Bell, D. Flieder, J. Paragas, G. P. Kobinger, N. A. Wivel, R. G. Crystal, J. Boyer, H. Feldmann, T. G. Voss, and J. M. Wilson. 2004. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J. Virol. 78: 11416-11421.
16. Hoogland, J. L. 1995. The black-tailed prairie dog: social life of a burrowing mammal, p. 221-259. The University of Chicago Press, Chicago, IL.
17. Hutson, C. L., V. A. Olson, D. S. Carroll, J. A. Abel, C. M. Hughes, Z. H. Braden, S. Weiss, J. Self, J. E. Osorio, P. N. Hudson, M. Dillon, K. L. Karem, I. K. Damon, and R. L. Regnery. 2009. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J. Gen. Virol. 90: 323-333.
18. Jackson, R. J., A. J. Ramsay, C. D. Christensen, S. Beaton, D. F. Hall, and I. A. Ramshaw. 2001. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75: 1205-1210.
19. Johnson, L. M., and P. Scott. 2007. STAT1 expression in dendritic cells, but not T cells, is required for immunity to Leishmania major. J. Immunol. 178: 7259-7266.
20. Karst, S. M., C. E. Wobus, M. Lay, J. Davidson, and H. W. Virgin. 2003. STAT1-dependent innate immunity to a Norwalk-like virus. Science 299: 1575-1578.
21. Langland, J. O., J. M. Cameron, M. C. Heck, J. K. Jancovich, and B. L. Jacobs. 2006. Inhibition of PKR by RNA and DNA viruses. Virus Res. 119: 100-110.
22. Langohr, I. M., G. W. Stevenson, H. L. Thacker, and R. L. Regnery. 2004. Extensive lesions of monkeypox in a prairie dog (Cynomys sp). Vet. Pathol. 41: 702-707.
23. Mann, B. A., J. H. Huang, P. Li, H. C. Chang, R. B. Slee, A. O'Sullivan, M. Anita, N. Yeh, M. J. Klemsz, R. R. Brutkiewicz, J. S. Blum, and M. H. Kaplan. 2008. Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J. Interferon Cytokine Res. 28: 367-380.
24. Marennikova, S. S., and E. M. Seluhina. 1976. Susceptibility of some rodent species to monkeypox virus, and course of the infection. Bull. World Health Organ. 53: 13-20.
25. McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3: 201-213.
26. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, K. Carver- Moore, R. N. DuBois, R. Clark, M. Aguet, and R. D. Schreiber. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
27. Moss, B., and P. L. Earl. 1998. Expression of proteins in mammalian cells using vaccinia virus vectors. Overview of the vaccinia virus expression system, p. 16.15.1-16.15.5. In Current protocols in molecular biology. Wiley, New York, NY.
28. Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208: 762-769.
29. Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
30. Mumphrey, S. M., H. Changotra, T. N. Moore, E. R. Heimann-Nichols, C. E. Wobus, M. J. Reilly, M. Moghadamfalahi, D. Shukla, and S. M. Karst. 2007. Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J. Virol. 81: 3251-3263.
31. Najarro, P., P. Traktman, and J. A. Lewis. 2001. Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J. Virol. 75: 3185-3196.
32. Nuara, A. A., H. Bai, N. Chen, R. M. Buller, and M. R. Walter. 2006. The unique C termini of orthopoxvirus gamma interferon binding proteins are essential for ligand binding. J. Virol. 80: 10675-10682.
33. Osorio, J. E., K. P. Iams, C. U. Meteyer, and T. E. Rocke. 2009. Comparison of monkeypox viruses pathogenesis in mice by in vivo imaging. PLoS One 4: e6592.
34. Panchanathan, V., G. Chaudhri, and G. Karupiah. 2008. Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol. Cell Biol. 86: 80-86.
35. Parker, S., L. Handley, and R. M. Buller. 2008. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol. 3: 595-612.
36. Parker, S., A. Nuara, R. M. Buller, and D. A. Schultz. 2007. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2: 17-34.
37. Parker, S., D. A. Schultz, H. Meyer, and R. L. Buller. 2008. Smallpox and monkeypox viruses, p. 639-644. In B. W. J. Mahy and N. H. V. Van Regenmortel (ed.), Encyclopedia of virology, Academic Press, Boston, MA.
38. Parker, S., A. M. Siddiqui, C. Oberle, E. Hembrador, R. Lanier, G. Painter, A. Robertson, and R. M. Buller. 2009. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 385: 11-21.
39. Parker, S., E. Touchette, C. Oberle, M. Almond, A. Robertson, L. C. Trost, B. Lampert, G. Painter, and R. M. Buller. 2008. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 77: 39-49.
40. Quenelle, D. C., R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, R. Jordan, and E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51: 689-695.
41. Quenelle, D. C., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48: 404-412.
42. Ramana, C. V., M. P. Gil, Y. Han, R. M. Ransohoff, R. D. Schreiber, and G. R. Stark. 2001. Stat1-independent regulation of gene expression in response to IFN-gamma. Proc. Natl. Acad. Sci. U. S. A. 98: 6674-6679.
43. Ramana, C. V., M. P. Gil, R. D. Schreiber, and G. R. Stark. 2002. Stat1-dependent and-independent pathways in IFN-gamma-dependent signaling. Trends Immunol. 23: 96-101.
44. Reed, L. J., and H. A. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hygiene 27: 493-497.
45. Rosas, L. E., T. Keiser, R. Pyles, J. Durbin, and A. R. Satoskar. 2003. Development of protective immunity against cutaneous leishmaniasis is dependent on STAT1-mediated IFN signaling pathway. Eur. J. Immunol. 33: 1799-1805.
46. Rothfuchs, A. G., C. Trumstedt, F. Mattei, G. Schiavoni, A. Hidmark, H. Wigzell, and M. E. Rottenberg. 2006. STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control of infection with Chlamydia pneumoniae by nonhemopoietic cells. J. Immunol. 176: 6982-6990.
47. Saijo, M., Y. Ami, Y. Suzaki, N. Nagata, N. Iwata, H. Hasegawa, I. Iizuka, T. Shiota, K. Sakai, M. Ogata, S. Fukushi, T. Mizutani, T. Sata, T. Kurata, I. Kurane, and S. Morikawa. 2009. Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates. J. Gen. Virol. 90: 2266-2271.
48. Sakala, I. G., G. Chaudhri, R. M. Buller, A. A. Nuara, H. Bai, N. Chen, and G. Karupiah. 2007. Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection. J. Virol. 81: 3346-3353.
49. Sbrana, E., S. Y. Xiao, P. C. Newman, and R. B. Tesh. 2007. Comparative pathology of North American and central African strains of monkeypox virus in a ground squirrel model of the disease. Am. J. Trop. Med. Hyg. 76: 155-164.
50. Schultz, D. A., J. E. Sagartz, D. L. Huso, and R. M. Buller. 2009. Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology 383: 86-92.
51. Shchelukhina, E. M., and S. S. Marennikova. 1975. [Generalized monkeypox in orally infected rabbits and white mice]. Vopr. Virusol. \?\November- December: 703-705. (In Russian.)
52. Shornick, L. P., A. G. Wells, Y. Zhang, A. C. Patel, G. Huang, K. Takami, M. Sosa, N. A. Shukla, E. Agapov, and M. J. Holtzman. 2008. Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infection. J. Immunol. 180: 3319-3328.
53. Shresta, S., K. L. Sharar, D. M. Prigozhin, H. M. Snider, P. R. Beatty, and E. Harris. 2005. Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice. J. Immunol. 175: 3946-3954.
54. Sugawara, I., H. Yamada, and S. Mizuno. 2004. STAT1 knockout mice are highly susceptible to pulmonary mycobacterial infection. Tohoku J. Exp. Med. 202: 41-50.
55. Tesh, R. B., D. M. Watts, E. Sbrana, M. Siirin, V. L. Popov, and S. Y. Xiao. 2004. Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus. Emerg. Infect. Dis. 10: 1563-1567.
56. Vancott, J. L., M. M. McNeal, A. H. Choi, and R. L. Ward. 2003. The role of interferons in rotavirus infections and protection. J. Interferon Cytokine Res. 23: 163-170.
57. Vancova, I., C. La Bonnardiere, and P. Kontsek. 1998. Vaccinia virus protein B18R inhibits the activity and cellular binding of the novel type interferondelta. J. Gen. Virol. 79: 1647-1649.
58. Vaughan, D. K., A. R. Gruber, M. L. Michalski, J. Seidling, and S. Schlink. 2006. Capture, care, and captive breeding of 13-lined ground squirrels, Spermophilus tridecemlineatus. Lab. Anim. (NY) 35: 33-40.
59. Wang, F., J. W. Barrett, Q. Shao, X. Gao, G. A. Dekaban, and G. McFadden. 2009. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2. Virology 387: 136-146.
60. Xiao, S. Y., E. Sbrana, D. M. Watts, M. Siirin, A. P. da Rosa, and R. B. Tesh. 2005. Experimental infection of prairie dogs with monkeypox virus. Emerg. Infect. Dis. 11: 539-545.
61. Xu, R. H., M. Cohen, Y. Tang, E. Lazear, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and L. J. Sigal. 2008. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med. 205: 981-992.
62. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79: 13139-13149.
63. Zaucha, G. M., P. B. Jahrling, T. W. Geisbert, J. R. Swearengen, and L. Hensley. 2001. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest. 81: 1581-1600.